Kornimate/medical-research-clean huggingface dataset:
proper duration of suppressive antibiotic therapy after debridement, antibiotics, and implant retention

Conditions: Periprosthetic Joint Infection; Antibiotic Suppression

Summary: multiple studies have demonstrated oral suppressive antibiotic therapy (sat), after intravenous antibiotics, maximizes reoperation-free survival of total joint arthroplasty (tja) debridement, antibiotics, and implant retention (dair) for acute periprosthetic joint infection (pji). however, little is known regarding sequelae of sat after dair for pji. prior studies have small or heterogeneous patient cohorts, variable antibiotic regimens, arrive at disparate conclusions, and do not establish antibiotic resistance risk. the investigators propose a prospective randomized controlled multicenter study to expand on findings in a retrospective, multi-center pilot study. study aims are to evaluate sat after dair of acutely infected primary tja regarding: 1) adverse drug reactions/intolerance; 2) reoperation for infection; and 3) antibiotic resistance.


Eligibility criteria:
inclusion criteria: * over 18 years-old * underwent dair with modular component exchange for acute tja pji, as defined by musculoskeletal infection society criteria, with symptom duration less than 4 weeks * on postoperative oral sat for at least 3 months exclusion criteria: * underwent aseptic revision surgery * had one-stage, 1.5-stage, or two-stage revision surgery * did not have postoperative sat * did not have follow-up that allowed for evaluation of sat sequelae
molecular and cellular mechanisms of the in-stent-thrombosis

Conditions: Patients With SAT or LT After Stent Implantation (PCI)

Summary: in-stent-thrombosis is a rare but serious complication after implantation of stents during ptca.

in this prospective, open, not-randomized, controlled single-center pilot study 80 patients having had an in-stent-thrombosis (40 sub-acute thromboses (sat), 40 late thromboses (lt)) and a control group of 80 patients having not developed a thrombosis will be compared. the aim of this study is the establishment of diagnostic markers vor prediction of sat (detection of cd39- and cd73-activity, respectively)and of lt (epc-number and function, respectively) correspondingly aiming at the early identification of patients with high risk for developing an in-stent-thrombosis.

Eligibility criteria:
inclusion criteria: * patients having developed an sat or lt after stent implantation using ptca exclusion criteria: * instabel coronary heart diseases, * systemic autoimmune diseases, * rheumatic diseases, * tumors, * impaired kidney or liver function, * surgery within the last 3 months, * pregnant or lactating women

Keywords: in-stent-thrombosis cd39 cd73 epc
pancreatic ductal adenocarcinoma - microbiome as predictor of subtypes

Conditions: Pancreatic Cancer

Summary: the prospective clinical trial "pda-maps - pancreatic ductal adenocarcinoma - microbiome as predictor of subtypes" aims to investigate the prognostic and predictive power of the orointestinal and tumoral microbiome in pdac patients and associate findings with genetic, transcriptional and clinical data, in particular with treatment response.

the prospective clinical trial "pda-maps - pancreatic ductal adenocarcinoma - microbiome as predictor of subtypes" aims to investigate the prognostic and predictive power of the orointestinal and tumoral microbiome in pdac patients and associate findings with genetic, transcriptional and clinical data, in particular with treatment response. patients with histologically confirmed pda are enrolled at primary diagnosis and prior to oncological or surgical treatment. rectal and buccal microbiome swabs as well as detailed clinical records are obtained from all patients. following dna extraction, both 16s rrna and metagenomic sequencing will be performed using ont sequencing platform. all data and clinical records are centrally stored, visualized and integrated via transmart and seek platforms.

Eligibility criteria:
inclusion criteria: - patients with pancreatic mass suspicious of pancreatic ductal adenocarcinoma exclusion criteria: * \< 18 years * patients that cannot give informed consent * pregnant and breastfeeding women
ndyag laser for acne keloidalis nuchae

Conditions: Acne Keloidalis Nuchae; NdYag Laser; AKN; Acne Keloidalis; AK; Dermatitis Papillaris Capillitii; Folliculitis Keloidalis Nuchae; Sycosis Nuchae; Acne Keloid; Keloidal Folliculitis; Lichen Keloidalis Nuchae; Folliculitis Nuchae Scleroticans; Sycosis Framboesiformis

Summary: acne keloidalis nuchae (akn) is a long standing hair follicle disease with bumps and scars on the skin of the back of the head and neck. the purpose of this new study is to determine how well a hair removal laser (ndyag laser) works in treating akn.


Eligibility criteria:
inclusion criteria: * for inclusion, the subject must: 1. be at least 18 years old 2. be otherwise healthy 3. have a diagnosis of akn with at least 10 papules/pustules and/or a non-keloidal plaque \> 7 cm2 in area. exclusion criteria: * subject must not: 1. have akn with a keloidal plaque \>3 cm in length 2. be using any other medications or undergoing any other procedures for the treatment of akn 3. have used any topical medications or undergone any procedures for the treatments of akn within two weeks of study enrollment 4. have used any oral medications for akn within 4 weeks of study enrollment: 5. have serious, uncontrolled medical conditions 6. be pregnant at any time during the study.

Keywords: acne keloidalis nuchae ndyag laser akn acne keloidalis ak dermatitis papillaris capillitii folliculitis keloidalis nuchae sycosis nuchae acne keloid keloidal folliculitis lichen keloidalis nuchae folliculitis nuchae scleroticans sycosis framboesiformis
treatment of egyptian hepatitis c genotype 4 infected children (and adolescents) with combined sofosbuvir & daclatasvir

Conditions: Hepatitis C Genotype 4

Summary: this is an open, uncontrolled pilot study of thirty chronic hcv infected patients carried out at yassin abdel ghaffar charity center for liver disease and research. the aim of this study is to investigate the safety \& efficacy of combined therapy sofosbuvir (sof) and daclatasvir (dcv) for treating hcv genotype 4 in children aged 8 to 18. due to previous positive results in other clinical studies of this drug it is expected that the drug will have high safety and high efficacy. safety will be measured by checking for adverse effects, while efficacy will be measured by real-time quantitative polymerase chain reaction (qpcr) detecting viral nucleic acids in blood samples.


Eligibility criteria:
inclusion criteria: 1. age: 8-18 years 2. sex: both sexes 3. naïve patients, with chronic hcv infection exclusion criteria: 1. co-infection with hepatitis b virus (hbv) 2. other associated chronic liver illness 3. cirrhotic patients (as indicated by biopsy, fibroscan(f4) 4. patients with history of hematemesis (non cirrhotic portal hypertension) 5. patients on drugs known to interact unfavorably with sof (amiodarone,..)
evaluation of neuropathic pain in the context of clinical symptoms, quantitative sensory tests and imaging with fmri

Conditions: Neuropathic Pain; Radiculopathy, Cervical

Summary: this study is planned to evaluate patients with upper extremity neuropathic pain due to cervical radiculopathy with clinical symptoms, quantitative sensory testing(qst) and functional magnetic resonance imaging(fmri). patients with similar charactheristics will be grouped and comparisons will be conducted in fmri results, as well as qst.

neuropathic pain is a type of pain which usually accompanies injuries or conduction defects in the central or peripheral nervous system, as well as receptors. unlike the other types of pain, neuropathic ones are more resistant to therapy and prone to be chronic. in recent years, there are many novel techiques to assess the neurological status and create standardized test protocols. one of these techiques is qst(quantitative sensory testing). qst is a specific type of sensory examination, usually done through computerized stimuli of heat, cold or vibration, or specific test equipment. there are many types of qst protocols around the world, and their results can also be expressed as phenotypes through statistics. while there are 3 types of pain phenotypes with the 13 item qst protocol suggested by german neuropathic pain research group(dfns), all patient groups can be classified differently as well, according to the common findings they express. these different phenotypes are also shown to have different responses to the different pain treatments. such differences are usually attributed to the different mechanisms and fibers underlying the pathogenesis. while patients show differences in qst results, evidence for the correlation between these variables and clinical symptoms of the patients are still scarce. moreover, it is still yet to be known if these differences have a central origin as well as the peripheral mechanisms. functional magnetic resonance imaging(fmri) is a method to evaluate cerebral functions. it is mainly based on the blood flow changes that occur locally in regions that are in function\[5\]. as a result of the increased blood flow, the oxygen concentration also increases, creating a signal response called bold(blood oxygen level dependent) response. since different types of pain are conducted through different fibers and pathways, it is also probable that they might show changes in cortical response as well. in this study, the aim is to find whether qst results are correlated to clinical symptoms and pain properties of the patients, and these changes are related to the changes in the central nervous system

Eligibility criteria:
inclusion criteria: adult patients with upper extremity neuropathic pain due to radiculopathy duration of \>1 month unilateral extremity pain exclusion criteria: * severe cognitive impairment * unstable systemic comorbidity * presence of pacemaker or deep brain stimulation * implants that aren't compatible with mri * claustrophobia * complete or near complete loss of sensation * brain injury or presence intracranial lesions
icu management of brain-dead donors before multi-organ procurement and factors associated with the number of organs retrieved

Conditions: Death, Brain

Summary: solid organ transplantation is the treatment of choice for end stage organ failure to improve patients' quality of life and survival. each year, more than 5,000 solid organ transplants are performed in france, mainly from brain death donors (bdd). approximately 1,500 bdd donors have one or more organs removed each year. despite the growing demand for transplanted organs, the number of organs available from deceased donors has remained stable over the past few decades. this highlights the need to optimize the management of potential bdd, in order to increase both the quality and number of transplanted organs. several studies have found an association between the characteristics and management of bdd donors and the number of organs, or even the function of transplanted organs. data suggest that hemodynamic, respiratory, and metabolic therapeutic targets during bdd management prior to multi-organ procurement were associated with a higher number of transplanted organs compared to standard care. however, this has never been confirmed in a french population. furthermore, while the impact of these therapeutic goals has been studied after the donor is in a state of brain death, the events occurring in the icu before reaching brain death status and their impact on the number of organs retrieved have not been investigated. lastly, the intensity of the therapeutic interventions used to achieve these goals, and certain management delays, have only been partially studied. our hypothesis is that achieving a bundle of therapeutic goals, and the intensity of the interventions used to reach these goals, both before and after bdd, are associated with a greater number of organs retrieved.


Eligibility criteria:
inclusion criteria: * patients over 18 years of age, hospitalized in the icu * in a state of brain death * no objection to organ donation during their lifetime * patients with social security coverage exclusion criteria: * objection to the use of their data during their lifetime * registration in the national refusal registry
medipore tape study

Conditions: Scarring

Summary: this is a prospective, single-blinded, two-arm, randomized, parallel, pragmatic, effectiveness trial that will enroll patients undergoing arthroscopic anterior cruciate ligament reconstruction in order to evaluate the efficacy of using medipore tape to improve cosmetic wound healing and scaring.


Eligibility criteria:
inclusion criteria: * all patients undergoing arthroscopic acl reconstruction with bone-patella-tendon-bone autograft at the ambulatory surgical center and hospital for joint diseases will be eligible for enrollment. * patient is indicated for acl reconstructive surgery with bone-patella-tendon-bone autograft exclusion criteria: * subjects/parents who are mentally impaired and are unable to give consent * patients with prior vertical anterior knee incisions * patients with known skin reactions to adhesive * patients with high risk for abnormal scar formation and keloids

Keywords: cosmetic wound healing anterior cruciate ligament (acl)
impact of forearm free flap in orbital exenteration reconstruction

Conditions: Cancer

Summary: orbital exenteration is the en bloc removal of the entire orbital contents. this mutilating surgical technique is reserved for the management of certain malignant orbito-palpebral tumors or those that secondarily invade the orbit. several types of exenteration have been described, more or less extended to the adjacent structures, with sometimes mixed ent-neurosurgical approaches for lesions invading the endocranium and causing large losses of substance. different surgical reconstruction techniques have been developed over the years, from spontaneous epithelialization to free osteo-muscular flap and temporal muscle transpositions. reconstruction after exenteration is essential to limit the sequelae and to allow the patient who has undergone this trauma to regain social interactions, a quality of life and an optimal self-image. the use of an antebrachial free flap would allow a faster healing and thus an earlier rehabilitation. the main objective of the study was to compare the morbidity of the antebrachial free flap with that of the temporal flap during exenteration and the rate of fitting of patients with epitheses.

reconstruction after exenteration is essential to limit the after-effects and to allow the patient who has suffered this trauma to regain social interaction, quality of life and self-image. the principal investigator hypothesize that reconstruction with a free antebrachial flap can improve the quality of life of an exentered patient while maintaining a low risk of intra- and post-operative morbidity. the aim of such a study will therefore be to provide assistance to both surgeons and patients, as to the choice of the technique of orbital reconstruction, by highlighting objectively and subjective evidence of the benefits of one technique over the other. the patients included in this study will have to answer two questionnaires, submitted by post or directly at the follow-up consultation. this study therefore falls within the framework of studies of minimal or moderate risk studies. they will be informed by telephone interview beforehand or directly in the consultation about the method of writing the questionnaires and their content.

Eligibility criteria:
inclusion criteria: * patients who were exentered and then reconstructed by free antebrachial flap or temporal muscle flap muscle flap at the institut curie paris, between january 2005 and december 2020. exclusion criteria: * legally protected patients * patients unable to give consent.

Keywords: forearm free flap orbital exenteration temporalis muscle flap quality of life
effect of fiasp® in type 1 diabetes treatment

Conditions: Diabetes Mellitus, Type 1

Summary: fiasp® is a meal-time insulin that has been available in sweden since june 2017. this study will investigate the effectiveness of fiasp® in treating type 1 diabetes mellitus. the study will be based on blood sugar measurements that the participants have uploaded to the diasend® database and on existing data in their electronic medical records. the study does not require any additional visits to the study doctor.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study (beyond identification of potential participants by searching for patients with type 1 diabetes diagnosis, fiasp® prescription information and electronic medical record (emr) data to identify continuous glucose monitoring (cgm)/flash glucose monitoring (fgm) use * age greater than or equal to 18 years at the time of signing informed consent * switched to a basal-bolus insulin regimen with fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin. switch must have occurred greater than or equal to 26 weeks prior to data collection and during 01 september 2017 to 31 august 2018 * treated with basal-bolus insulin regimen throughout the 26 weeks prior to fiasp® initiation * treated with the same basal insulin, i.e. no records of switching the basal insulin, during the 26 weeks prior to fiasp® initiation or the 26 weeks after fiasp® initiation * diagnosed with type 1 diabetes for greater than or equal to 12 months prior to fiasp® initiation * use of cgm/fgm during the 26 weeks prior to fiasp® initiation and the 26 weeks after fiasp® initiation * use of the same cgm/fgm device during the full 26-week period after fiasp® initiation. exclusion criteria: * previous participation in this study. participation is defined as signed informed consent * participation in clinical study with receipt of any investigational medicinal product known to affect glucose control during the 26-week period prior to fiasp® initiation or the 26-week period after fiasp® initiation * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * patients prescribed any other glucose-lowering drugs than insulins (anatomical therapeutic chemical \[atc\] class a10b), including oral and injectable drugs, as addition to their insulin treatment during the 26-week period prior to fiasp® initiation or the 26-week period after fiasp® initiation * use of fiasp® as bolus insulin during the 26-week period prior to fiasp® initiation * use of any insulin with an insulin pump (i.e. continuous subcutaneous insulin infusion) during the 26-week period prior to fiasp® initiation or the 26-week period after fiasp® initiation.
s-icd french cohort study (honest)

Conditions: Sudden Cardiac Death; Implantable Defibrillator User

Summary: implantable cardioverter-defibrillators have been proven to be effective in the prevention of sudden cardiac death in high-risk patients. however, it is well acknowledged that such a strategy could be optimised, especially through new technologies/devices. data on the entirely sub-cutaneous implantable cardioverter defibrillator (s-icd) published so far come from high-volume centers and/or selected populations. the honest cohort -taking the opportunity of a unique scenario with a single manufacturer and remote monitoring system available- aims to collect retrospectively baseline information as well as follow-up of all patients implanted with an s-icd in france since the first implant in october 13, 2012 until december 31, 2019. an extended prospective yearly follow-up will be carried out since january 1, 2020 until december 31, 2024.


Eligibility criteria:
inclusion criteria: * all patients who require s-icd implantation (new or battery replacement) exclusion criteria: * refusal of consent

Keywords: outcomes appropriate shock complications subcutaneous
complete infarct related artery revascularization

Conditions: Myocardial Infarction; Coronary Artery Disease

Summary: corami trial is a prospective, international, multicenter randomized study which will be performed in experienced invasive facility centres with 24/7 pci (percutaneous coronary intervention) duty and patient enrollment will continue for 18 months (october 2010 - march 2012).the aim of the study is to compare strategy of complete vs target lesion-only primary pci in ira (infarct related artery) in stemi (st elevation myocardial infarction) patients.


Eligibility criteria:
inclusion criteria: * diagnosis of stemi (according to esc 2007 definition) * chest pain onset \<12 hours * signed informed consent * presence of two critical lesions requiring pci in ira (lad - left anterior descending, cx - circumflex, rca - right coronary artery) * target/culprit lesion which requires immediate stenting (\>50 - 100%) and second critical lesion (70-90%) with timi 3 flow after pci of the 1st target/culprit lesion * over 18 years of age * ira diameter ≥ 2.5 mm exclusion criteria: * terminal illness with life expectancy less \<1 year or active cancer disease - pregnancy or possibility of pregnancy * second critical lesion in ira \>90% or occlusion * contraindications to pci or/and stent implantation * contraindications to des stent implantation * lesion diameters unsuitable for intended stent platform * active bleeding or coagulopathy * patient in cardiogenic shock (\<90mmhg sbp and/or requiring iabp - intraaortic balloon pump - or vasopressors) - killip 4 class * patient has left bundle branch block (lbbb) or pacemaker rhythm * no future patient cooperation expected * patient is participating in another clinical study
prospective study investigating aspirin and intraoperative blood loss and complications following inguinal hernia repair

Conditions: Hernia, Inguinal; Postoperative Complications; Postoperative Hemorrhage

Summary: the purpose of this study is to determine whether aspirin taken in the perioperative period will increase the blood loss associated with open inguinal hernia repairs. a secondary purpose of this study is to determine if the aspirin administered in the perioperative period increases the risk of complications associated with open inguinal hernia repairs.

this is a prospective, non-randomized, study which compares the use of 81mg of aspirin, 325mg of aspirin or no aspirin in adult men undergoing an open tension free mesh inguinal hernia repair. subjects currently taking 81mg or 325mg of aspirin will undergo inguinal hernia repair without having their medications stopped. patient not currently taking aspirin will act as controls. intraoperative blood loss will be measured utilizing a gravimetric method by weighing surgical sponges before and after use. subjects will be followed for thirty days postoperatively and be evaluated for bleeding complications. the specific complications include wound or scrotal hematomas, return to the operating room within 72 hour for bleeding, wound infection, early recurrent hernia, excessive wound ecchymosis.

Eligibility criteria:
inclusion criteria: * adult male veterans ages 18-99 * inguinal hernia * subjects currently taking 81mg, 325mg or no aspirin exclusion criteria: * recurrent hernia * "giant" hernia * women * international normalized ratio \> 1.7 * hemophilia or other know congenital bleeding disorder * cirrhosis of hepatitis with coagulopathy * thrombocytopenia with platelet counts \< 100,000 * subjects currently on coumadin or other platelet inhibitors

Keywords: aspirin postoperative hemorrhage inguinal hernia